Valuation: Alpha Cognition Inc.

Capitalization 182M 131M 112M 105M 97.46M 11.82B 196M 1.21B 474M 5.65B 491M 481M 20.83B P/E ratio 2025 *
-5.9x
P/E ratio 2026 * -4.87x
Enterprise value 182M 131M 112M 105M 97.46M 11.82B 196M 1.21B 474M 5.65B 491M 481M 20.83B EV / Sales 2025 *
11.7x
EV / Sales 2026 * 5.42x
Free-Float
88.93%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data

Last Transcript: Alpha Cognition Inc.

Manager TitleAgeSince
Chief Executive Officer 59 12/04/2021
Chief Tech/Sci/R&D Officer - 22/03/2021
Director of Finance/CFO - 21/10/2024
Director TitleAgeSince
Chairman - 22/03/2021
Director/Board Member - 22/03/2021
Director/Board Member 66 22/03/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-.--%-.--% - - 131M
-0.35%+1.24%+35.07%+197.88% 964B
+1.87%+4.33%+47.89%+23.19% 515B
+0.32%-1.42%+24.90%+43.72% 390B
+0.73%+1.77%+30.68%+16.84% 363B
+2.13%+0.67%+34.71%+22.64% 292B
+1.44%+1.50%+27.95%+33.73% 272B
-0.85%-0.56%+7.21%-3.55% 269B
-0.80%+3.83%-35.77%-20.13% 265B
-0.38%-1.78%+20.03%+19.35% 175B
Average +0.34%+1.35%+21.41%+37.07% 389.45B
Weighted average by Cap. +0.31%+1.56%+26.54%+68.14%
See all sector performances

Financials

2025 *2026 *
Net sales 15.5M 11.16M 9.59M 8.94M 8.31M 1.01B 16.72M 103M 40.39M 482M 41.84M 40.99M 1.78B 33.53M 24.13M 20.74M 19.34M 17.97M 2.18B 36.15M 222M 87.36M 1.04B 90.5M 88.65M 3.84B
Net income -24.78M -17.83M -15.32M -14.29M -13.28M -1.61B -26.71M -164M -64.55M -770M -66.88M -65.5M -2.84B -37.48M -26.98M -23.18M -21.62M -20.09M -2.44B -40.42M -249M -97.65M -1.16B -101M -99.1M -4.29B
Net Debt - -
More financial data * Estimated data
Logo Alpha Cognition Inc.
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.
Employees
-
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.020USD
Average target price
20.00USD
Spread / Average Target
+232.23%
Consensus

Quarterly revenue - Rate of surprise